Neurolign Technologies Inc. Acquires Neuro Kinetics Inc.
On September 20th, 2019, Neurolign Technologies Inc. (“Neurolign”), announced the acquisition of Neuro Kinetics Inc. (“NKI”) of Pittsburgh, Pennsylvania. Neuro Kinetics Inc. is a leader in its field, providing eye-tracking diagnostic platforms that deliver, leading edge, neuro-functional assessments and monitoring to identify more than 200 diseases and medical conditions (www.neuro-kinetics.com). With over 90 variables and 14 FDA cleared tests, NKI has the most precise and data-rich eye-tracking solution in the Global market to date. NKI’s solutions, including its key assets, I-PAS™ and I-Portal™ are foundational platforms helping clinicians detect multiple medical conditions early, accurately, and cost effectively. I-Portal’s non-invasive Science to See™ is enabling NKI to expand its presence from its historic vestibular market into new arenas and applications in traumatic brain injury, concussion, ophthalmology, and neurology. “With this investment in NKI, we are on a rapid trajectory to provide objective and novel approaches, becoming the preeminent leader in neurological diagnostics and therapeutics impacting all dimensions of brain health”, added CEO Eugene Melnyk. To read more click here.
Learn more about Neurolign today!
Speak to an expert to find out how Neurolign could be integrated into your practice.